ECI1

Summary

ECI1 (enoyl-CoA delta isomerase 1, HGNC:2703) is a protein-coding gene on chromosome 16p13.3, encoding Enoyl-CoA delta isomerase 1, mitochondrial (P42126). Key enzyme of fatty acid beta-oxidation.

This gene encodes a member of the hydratase/isomerase superfamily. The protein encoded is a key mitochondrial enzyme involved in beta-oxidation of unsaturated fatty acids. It catalyzes the transformation of 3-cis and 3-trans-enoyl-CoA esters arising during the stepwise degradation of cis-, mono-, and polyunsaturated fatty acids to the 2-trans-enoyl-CoA intermediates. Alternatively spliced transcript variants have been described.

Source: NCBI Gene 1632 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 98 total
• Druggable target: yes
• MANE Select transcript: NM_001919

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:2703
Approved symbol	ECI1
Name	enoyl-CoA delta isomerase 1
Location	16p13.3
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000167969
Ensembl biotype	protein_coding
OMIM	600305
Entrez	1632

Gene structure

Transcript identifiers

Ensembl transcripts: 13 — 10 protein_coding, 3 retained_intron

ENST00000301729, ENST00000561688, ENST00000562238, ENST00000563029, ENST00000563447, ENST00000566379, ENST00000570258, ENST00000857514, ENST00000857515, ENST00000857516, ENST00000957379, ENST00000957380, ENST00000957381

RefSeq mRNA: 2 — MANE Select: NM_001919 NM_001178029, NM_001919

CCDS: CCDS10464, CCDS58410

Canonical transcript exons

ENST00000301729 — 7 exons

Exon	Start	End
ENSE00001118810	2243046	2243224
ENSE00001118812	2239402	2240145
ENSE00001197484	2251515	2251587
ENSE00003473627	2251316	2251429
ENSE00003482375	2243318	2243439
ENSE00003585563	2246859	2246986
ENSE00003588462	2244406	2244552

Expression profiles

Bgee: expression breadth ubiquitous, 280 present calls, max score 98.67.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 54.8052 / max 539.4646, expressed in 1818 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
155916	54.8052	1818

Top tissues by expression

293 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
apex of heart	UBERON:0002098	98.67	gold quality
hindlimb stylopod muscle	UBERON:0004252	97.93	gold quality
right lobe of liver	UBERON:0001114	97.82	gold quality
gastrocnemius	UBERON:0001388	97.64	gold quality
right atrium auricular region	UBERON:0006631	97.32	gold quality
right lobe of thyroid gland	UBERON:0001119	97.26	gold quality
heart left ventricle	UBERON:0002084	97.25	gold quality
mucosa of transverse colon	UBERON:0004991	97.06	gold quality
cardiac ventricle	UBERON:0002082	97.02	gold quality
left lobe of thyroid gland	UBERON:0001120	97.00	gold quality
muscle of leg	UBERON:0001383	96.84	gold quality
cardiac atrium	UBERON:0002081	96.48	gold quality
thyroid gland	UBERON:0002046	96.18	gold quality
metanephros cortex	UBERON:0010533	96.10	gold quality
muscle organ	UBERON:0001630	96.01	gold quality
transverse colon	UBERON:0001157	95.95	gold quality
heart	UBERON:0000948	95.90	gold quality
lower esophagus muscularis layer	UBERON:0035833	95.48	gold quality
body of stomach	UBERON:0001161	95.47	gold quality
lower esophagus	UBERON:0013473	95.47	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	95.26	gold quality
muscle layer of sigmoid colon	UBERON:0035805	95.26	gold quality
triceps brachii	UBERON:0001509	95.12	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	95.12	gold quality
liver	UBERON:0002107	95.09	gold quality
right uterine tube	UBERON:0001302	94.89	gold quality
adult mammalian kidney	UBERON:0000082	94.74	gold quality
minor salivary gland	UBERON:0001830	94.65	gold quality
mucosa of stomach	UBERON:0001199	94.63	gold quality
saliva-secreting gland	UBERON:0001044	94.60	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-MTAB-10287	yes	46.72
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 3)

• determination of structure and mode of binding for fatty acyl group (PMID:15351645)
• Hepatitis C virus growth and RNA replication in hepatoma cell lines stably expressing coenzyme A delta isomerase (DCI)-targeting short hairpin RNA (shRNA) were abrogated, indicating that DCI is required for productive infection. (PMID:21917952)
• Fatty acid oxidation enzyme Delta3, Delta2-enoyl-CoA isomerase 1 (ECI1) drives aggressive tumor phenotype and predicts poor clinical outcome in prostate cancer patients. (PMID:35411033)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	eci1	ENSDARG00000018002
mus_musculus	Eci1	ENSMUSG00000024132
rattus_norvegicus	Eci1	ENSRNOG00000008843
drosophila_melanogaster	CG4598	FBGN0032160
drosophila_melanogaster	CG4594	FBGN0032161
drosophila_melanogaster	CG4592	FBGN0032162

Paralogs (13): ECHDC1 (ENSG00000093144), ECH1 (ENSG00000104823), ECHDC2 (ENSG00000121310), ECHS1 (ENSG00000127884), CDY2B (ENSG00000129873), ECHDC3 (ENSG00000134463), AUH (ENSG00000148090), CDYL (ENSG00000153046), CDYL2 (ENSG00000166446), CDY1 (ENSG00000172288), CDY1B (ENSG00000172352), CDY2A (ENSG00000182415), HIBCH (ENSG00000198130)

Protein

Protein identifiers

Enoyl-CoA delta isomerase 1, mitochondrial — P42126 (reviewed: P42126)

Alternative names: 3,2-trans-enoyl-CoA isomerase, Delta(3),Delta(2)-enoyl-CoA isomerase, Dodecenoyl-CoA isomerase

All UniProt accessions (4): P42126, A0A384NKJ3, H3BS70, Q96DC0

UniProt curated annotations — full annotation on UniProt →

Function. Key enzyme of fatty acid beta-oxidation. Able to isomerize both 3-cis (3Z) and 3-trans (3E) double bonds into the 2-trans (2E) form in a range of enoyl-CoA species, with a preference for (3Z)-enoyl-CoAs over (3E)-enoyl-CoAs. The catalytic efficiency of this enzyme is not affected by the fatty acyl chain length.

Subunit / interactions. Homotrimer.

Subcellular location. Mitochondrion matrix.

Tissue specificity. Expressed in liver (at protein level).

Pathway. Lipid metabolism; fatty acid beta-oxidation.

Similarity. Belongs to the enoyl-CoA hydratase/isomerase family.

Isoforms (2)

UniProt ID	Names	Canonical?
P42126-1	1	yes
P42126-2	2

RefSeq proteins (2): NP_001171500, NP_001910* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001753	Enoyl-CoA_hydra/iso	Domain
IPR018376	Enoyl-CoA_hyd/isom_CS	Conserved_site
IPR029045	ClpP/crotonase-like_dom_sf	Homologous_superfamily

Pfam: PF00378

Enzyme classification (BRENDA):

• EC 5.3.3.8 — DELTA3-DELTA2-enoyl-CoA isomerase (BRENDA: 14 organisms, 65 substrates, 8 inhibitors, 70 Km, 69 kcat entries)

Substrate kinetics (BRENDA)

19 substrates with measured Km, best-characterized 15. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
3-TRANS-HEXENOYL-COA	0.03–1.6	15
TRANS-3-HEXENOYL-COA	0.03–0.12	7
3-CIS-HEXENOYL-COA	0.031–1.2	6
3-CIS-TETRADECENOYL-COA	0.006–0.089	5
2-TRANS,5-CIS-OCTADIENOYL-COA	0.0044–0.17	3
2-TRANS,5-CIS-TETRADECADIENOYL-COA	0.0096–0.029	3
3-CIS-OCTENOYL-COA	0.032–0.15	3
3-DECYNOYL-N-ACETYLCYSTEAMINE	0.24–0.81	3
3-DODECYNOYL-N-ACETYLCYSTEAMINE	0.28–0.97	3
3-HEXYNOYL-N-ACETYLCYSTEAMINE	2.1–7.2	3
3-OCTYNOYL-N-ACETYLCYSTEAMINE	0.68–1.6	3
3-TRANS-OCTENOYL-COA	0.028–0.19	3
3-TRANS-TETRADECENOYL-COA	0.029–0.048	3
TRANS-2-HEXENOYL-COA	0.0006–0.31	3
3-HEXENOYL-COA	0.04–0.15	2

Catalyzed reactions (Rhea), 7 shown:

• (3Z)-dodecenoyl-CoA = (2E)-dodecenoyl-CoA (RHEA:23716)
• (2E)-tetradecenoyl-CoA = (3Z)-tetradecenoyl-CoA (RHEA:29847)
• a (3E)-enoyl-CoA = a 4-saturated (2E)-enoyl-CoA (RHEA:45228)
• (3Z)-hexenoyl-CoA = (2E)-hexenoyl-CoA (RHEA:45748)
• a (3Z)-enoyl-CoA = a 4-saturated (2E)-enoyl-CoA (RHEA:45900)
• (3Z)-octenoyl-CoA = (2E)-octenoyl-CoA (RHEA:46044)
• (3Z)-decenoyl-CoA = (2E)-decenoyl-CoA (RHEA:77195)

UniProt features (54 total): sequence conflict 15, helix 14, strand 8, modified residue 7, binding site 3, turn 2, transit peptide 1, chain 1, splice variant 1, mutagenesis site 1, site 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
1SG4	X-RAY DIFFRACTION	1.3

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P42126-F1	90.43	0.86

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 178 (important for catalytic activity)

Ligand- & substrate-binding residues (3): 106–110; 153; 177

Post-translational modifications (7): 283, 283, 288, 61, 61, 84, 89

Mutagenesis-validated functional residues (1):

Position	Phenotype
178	loss of activity.

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-77288	mitochondrial fatty acid beta-oxidation of unsaturated fatty acids
R-HSA-9837999	Mitochondrial protein degradation

MSigDB gene sets: 215 (showing top): GSE18804_BRAIN_VS_COLON_TUMORAL_MACROPHAGE_DN, GSE18804_SPLEEN_MACROPHAGE_VS_COLON_TUMORAL_MACROPHAGE_DN, GOBP_LIPID_MODIFICATION, GOBP_FATTY_ACID_CATABOLIC_PROCESS, MODULE_151, GOLDRATH_IMMUNE_MEMORY, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, DACOSTA_UV_RESPONSE_VIA_ERCC3_UP, GOBP_MONOCARBOXYLIC_ACID_METABOLIC_PROCESS, HUMMERICH_SKIN_CANCER_PROGRESSION_DN, YGACNNYACAR_UNKNOWN, MCBRYAN_PUBERTAL_BREAST_4_5WK_DN, HOSHIDA_LIVER_CANCER_SUBCLASS_S3, BLALOCK_ALZHEIMERS_DISEASE_UP, GOBP_ORGANIC_ACID_CATABOLIC_PROCESS

GO Biological Process (3): fatty acid beta-oxidation (GO:0006635), lipid metabolic process (GO:0006629), fatty acid metabolic process (GO:0006631)

GO Molecular Function (4): delta(3)-delta(2)-enoyl-CoA isomerase activity (GO:0004165), intramolecular oxidoreductase activity, transposing C=C bonds (GO:0016863), catalytic activity (GO:0003824), isomerase activity (GO:0016853)

GO Cellular Component (2): mitochondrion (GO:0005739), mitochondrial matrix (GO:0005759)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Mitochondrial Fatty Acid Beta-Oxidation	1
Metabolism of proteins	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
fatty acid catabolic process	1
fatty acid ligase activity	1
fatty acid oxidation	1
primary metabolic process	1
lipid metabolic process	1
monocarboxylic acid metabolic process	1
intramolecular oxidoreductase activity, transposing C=C bonds	1
intramolecular oxidoreductase activity	1
molecular_function	1
catalytic activity	1
cytoplasm	1
intracellular membrane-bounded organelle	1
mitochondrion	1
intracellular organelle lumen	1

Protein interactions and networks

STRING

2524 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ECI1	ECI2	O75521	985
ECI1	DECR1	Q16698	621
ECI1	ACAA2	P42765	599
ECI1	ACADS	P16219	556
ECI1	HADHB	P55084	545
ECI1	ETFDH	Q16134	544
ECI1	HSD17B4	P51659	543
ECI1	ACADL	P28330	539
ECI1	ACADM	P11310	534
ECI1	CPT2	P23786	516
ECI1	ACADVL	P49748	507
ECI1	DECR2	Q9NUI1	496
ECI1	EHHADH	Q08426	480
ECI1	ACOX3	O15254	463
ECI1	ACADSB	P45954	456

IntAct

14 interactions, top by confidence:

A	B	Type	Score
LMTK3	GPI	psi-mi:“MI:0914”(association)	0.420
ECI1	POT1	psi-mi:“MI:0915”(physical association)	0.370
MAPKAP1	ECI1	psi-mi:“MI:0915”(physical association)	0.370
FASTKD3	VWA8	psi-mi:“MI:0914”(association)	0.350
HSCB	RBP5	psi-mi:“MI:0914”(association)	0.350
RAB9A	LANCL1	psi-mi:“MI:0914”(association)	0.350
LRRK2		psi-mi:“MI:0914”(association)	0.350
FBXL19	S100A9	psi-mi:“MI:0914”(association)	0.350
	DENND11	psi-mi:“MI:0914”(association)	0.350
VCP	FAM171A2	psi-mi:“MI:0914”(association)	0.350
MRPL58		psi-mi:“MI:0914”(association)	0.350
HSPD1	VWA8	psi-mi:“MI:2364”(proximity)	0.270

BioGRID (77): ECI1 (Co-fractionation), ECI1 (Co-fractionation), ECI1 (Co-fractionation), HIBCH (Co-fractionation), ECI1 (Affinity Capture-RNA), ECI1 (Affinity Capture-MS), ECI1 (Proximity Label-MS), ECI1 (Affinity Capture-MS), ECI1 (Proximity Label-MS), ECI1 (Co-fractionation), HMGCS1 (Co-fractionation), CHID1 (Co-fractionation), ACP6 (Co-fractionation), NFU1 (Co-fractionation), ECI1 (Co-fractionation)

ESM2 similar proteins: A6QP05, A9JS71, F1NB38, F1R6N4, O35459, P11172, P13439, P17256, P23965, P31754, P42125, P42126, Q03426, Q0V8R7, Q13011, Q28C91, Q28DB5, Q2HJD5, Q3MIE0, Q3URE1, Q4G176, Q58DN7, Q5E9H9, Q5E9T8, Q5HZQ8, Q5R4W0, Q5R514, Q5R824, Q5REX5, Q5RFG0, Q62651, Q62904, Q64323, Q6AYG5, Q6GLK6, Q6GM82, Q6NYL5, Q6PE15, Q7T0X7, Q8BGT5

Diamond homologs: A0KV76, A1ADI8, A1S7L6, A3CYJ4, A3QFP3, A4WCW6, A4XSM8, A5WH99, A6TC19, A7N1D2, A7ZPF8, A8A2L0, A8ADP2, A8G8D1, A9N453, B0KH74, B1IXA5, B1LME7, B1X9L4, B2TWV4, B4SZR0, B4TCA8, B4TQC2, B5BBA1, B5EZR9, B5FPN1, B5R3R9, B5RCL3, B5XVW2, B5YXY4, B6I6Q4, B7LBJ5, B7LLD0, B7M6M2, B7MGV7, B7MY16, B7N5V2, B7NP24, B7UFZ8, B7VGL4

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

98 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	73
Likely benign	5
Benign	3

Top pathogenic / likely-pathogenic (0)

SpliceAI

1207 predictions. Top by Δscore:

Variant	Effect	Δscore
16:2240142:TGGT:T	acceptor_gain	1.0000
16:2240145:TC:T	acceptor_loss	1.0000
16:2240146:C:CC	acceptor_gain	1.0000
16:2240147:T:C	acceptor_loss	1.0000
16:2243220:TCAAC:T	acceptor_gain	1.0000
16:2243221:CAAC:C	acceptor_gain	1.0000
16:2243221:CAACC:C	acceptor_gain	1.0000
16:2243222:AAC:A	acceptor_gain	1.0000
16:2243223:AC:A	acceptor_gain	1.0000
16:2243223:ACC:A	acceptor_loss	1.0000
16:2243224:CC:C	acceptor_gain	1.0000
16:2243224:CCT:C	acceptor_loss	1.0000
16:2243225:C:CC	acceptor_gain	1.0000
16:2243225:CTGGA:C	acceptor_loss	1.0000
16:2243311:GCCTT:G	donor_loss	1.0000
16:2243312:CCTTA:C	donor_loss	1.0000
16:2243313:CTTA:C	donor_loss	1.0000
16:2243314:TTA:T	donor_loss	1.0000
16:2243315:TA:T	donor_loss	1.0000
16:2243436:CTCC:C	acceptor_gain	1.0000
16:2243437:TCC:T	acceptor_gain	1.0000
16:2243438:CC:C	acceptor_gain	1.0000
16:2243438:CCC:C	acceptor_gain	1.0000
16:2243439:CC:C	acceptor_gain	1.0000
16:2243439:CCTG:C	acceptor_loss	1.0000
16:2243440:C:CC	acceptor_gain	1.0000
16:2243440:CTGCA:C	acceptor_loss	1.0000
16:2243441:T:G	acceptor_loss	1.0000
16:2244404:A:AC	donor_gain	1.0000
16:2244405:C:CC	donor_gain	1.0000

AlphaMissense

1928 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
16:2240123:C:A	K255N	0.995
16:2240123:C:G	K255N	0.995
16:2240136:C:G	R251P	0.994
16:2243319:A:G	W188R	0.993
16:2243319:A:T	W188R	0.993
16:2240112:C:G	R259P	0.992
16:2243396:T:A	D162V	0.991
16:2243431:G:C	C150W	0.990
16:2246949:G:C	N68K	0.990
16:2246949:G:T	N68K	0.990
16:2243390:C:G	R164P	0.989
16:2243438:C:T	G148E	0.989
16:2244535:G:C	F104L	0.989
16:2244535:G:T	F104L	0.989
16:2244537:A:G	F104L	0.989
16:2243357:C:T	G175E	0.988
16:2243117:T:A	D224V	0.987
16:2243163:C:A	G209W	0.985
16:2243396:T:G	D162A	0.985
16:2244453:A:G	W132R	0.985
16:2244453:A:T	W132R	0.985
16:2243398:A:C	C161W	0.984
16:2243397:C:A	D162Y	0.982
16:2244419:A:T	V143D	0.982
16:2243391:G:T	R164S	0.981
16:2243433:A:G	C150R	0.981
16:2243120:A:T	V223E	0.980
16:2243418:A:G	C155R	0.979
16:2243438:C:A	G148V	0.979
16:2246875:C:T	G93D	0.978

dbSNP variants (sampled 300 via entrez): RS1000088254 (16:2250045 T>G), RS1000303889 (16:2241410 C>G), RS1000326445 (16:2252061 TG>T), RS1000359220 (16:2250555 G>A,C,T), RS1000411169 (16:2245406 G>A), RS1000710985 (16:2250328 T>C), RS1000753426 (16:2239156 C>T), RS1000997342 (16:2243347 C>A,G), RS1001179360 (16:2242147 C>A,G,T), RS1001195667 (16:2249536 G>C,T), RS1001233060 (16:2244925 T>C), RS1001356470 (16:2240761 A>G), RS1001358369 (16:2242791 T>A,C), RS1001482484 (16:2250903 C>T), RS1001661277 (16:2245077 G>A,C)

Disease associations

OMIM: gene MIM:600305 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST007490_26	Anthropometric traits (multi-trait analysis)	1.000000e-11
GCST90011900_122	Serum alkaline phosphatase levels	2.000000e-09

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0004324	body weights and measures
EFO:0004533	alkaline phosphatase measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL6066903 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

2 potent at pChembl≥5 of 4 total, top 2 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
5.30	Kd	5015	nM	CHEMBL3752910
5.30	ED50	5015	nM	CHEMBL3752910

PubChem BioAssay actives

1 with measured affinity, of 4 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(1-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148281: Binding affinity to human ECI1 incubated for 45 mins by Kinobead based pull down assay	kd	5.0151	uM

CTD chemical–gene interactions

44 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases expression, increases methylation	4
sodium arsenite	decreases expression, increases abundance, increases expression	2
Arsenic	affects methylation, decreases expression, increases abundance	2
Tobacco Smoke Pollution	affects expression, increases expression	2
Tretinoin	increases expression	2
aristolochic acid I	decreases expression, increases expression	1
bisphenol F	increases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	increases expression	1
methylselenic acid	decreases expression	1
beta-lapachone	decreases expression	1
zinc chromate	increases abundance, decreases expression	1
ochratoxin A	decreases expression	1
tamibarotene	affects expression	1
di-n-butylphosphoric acid	affects expression	1
chromium hexavalent ion	decreases expression, increases abundance	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
ICG 001	increases expression	1
bisphenol B	increases expression	1
pyrachlostrobin	decreases expression	1
jinfukang	increases expression	1
LDN 193189	affects cotreatment, increases expression	1
picoxystrobin	decreases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	increases expression	1
Temozolomide	increases expression	1
Sunitinib	increases expression	1
Arsenic Trioxide	decreases response to substance	1
Air Pollutants	decreases expression, increases abundance	1
Antimycin A	decreases expression	1
Atrazine	decreases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5651323	Binding	Binding affinity to human ECI1 incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.